Brookmont Capital Management Buys 21,725 Shares of Novo Nordisk A/S $NVO

Brookmont Capital Management grew its stake in Novo Nordisk A/S (NYSE:NVO) by 38.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 78,858 shares of the company’s stock after buying an additional 21,725 shares during the quarter. Novo Nordisk A/S accounts for approximately 2.4% of Brookmont Capital Management’s portfolio, making the stock its 7th biggest position. Brookmont Capital Management’s holdings in Novo Nordisk A/S were worth $4,376,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Beacon Financial Group lifted its stake in Novo Nordisk A/S by 4.3% in the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after acquiring an additional 178 shares during the last quarter. Kavar Capital Partners Group LLC raised its holdings in shares of Novo Nordisk A/S by 0.6% in the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock valued at $1,811,000 after purchasing an additional 200 shares in the last quarter. SeaBridge Investment Advisors LLC lifted its position in shares of Novo Nordisk A/S by 5.7% during the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock worth $207,000 after purchasing an additional 200 shares during the last quarter. Joel Isaacson & Co. LLC grew its stake in shares of Novo Nordisk A/S by 1.0% during the third quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock worth $1,170,000 after purchasing an additional 200 shares in the last quarter. Finally, Revolve Wealth Partners LLC increased its holdings in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 16.3%

NVO opened at $39.68 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 52 week low of $39.34 and a 52 week high of $93.80. The business’s 50 day moving average is $53.56 and its two-hundred day moving average is $53.23. The firm has a market cap of $177.16 billion, a price-to-earnings ratio of 11.43 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Underlying commercial momentum remains: Novo still reports strong Wegovy/Ozempic-era sales and recent quarterly beats that support cash flow and dividends; that steady franchise cushions the setback. Wegovy Growth Beats Expectations
• Neutral Sentiment: Broader market weakness (tariff news, lower futures) amplified NVO’s move today, so part of the decline reflects market context rather than company‑only news. 5 Things to Know Before the Stock Market Opens
• Negative Sentiment: REDEFINE‑4 trial missed its primary non‑inferiority goal: CagriSema produced less weight loss than Lilly’s tirzepatide, raising concerns about Novo’s ability to defend/expand obesity market share. REDEFINE‑4 Trial Results
• Negative Sentiment: Head‑to‑head efficacy gap quantified in market coverage (example: 20.2% average weight loss for CagriSema vs 23.6% for tirzepatide over 84 weeks), a concrete metric investors view as clinically and commercially meaningful. CagriSema vs Tirzepatide Results
• Negative Sentiment: Analyst reaction and legal risk: at least one major shop downgraded NVO to hold and law firms have opened investor investigations alleging possible misstatements, which can increase short‑term selling and volatility. Analyst Downgrade Fraud Investigation Notice
• Negative Sentiment: Market cap and sentiment impact: coverage notes the stock hit multi‑year lows and investors marked off billions in valuation as the market repriced Novo’s obesity growth prospects. Market Reaction / Valuation Impact

Analyst Ratings Changes

NVO has been the subject of a number of recent analyst reports. TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Deutsche Bank Aktiengesellschaft cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday. The Goldman Sachs Group reiterated a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Finally, Citigroup began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. Seven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.